Review of the association between periodontitis and chronic obstructive pulmonary disease in smokers

Agathi Spiropoulou1,2, Nicholas Zareifopoulos2, Aggeliki Bellou2, Kostas Spiropoulos1, Lazaros Tsalikis1
1School of Dentistry, Aristotle University of Thessaloniki; 2Department of Pulmonology, School of Medicine, University of Patras, Greece

Abstract

Both periodontitis and chronic obstructive pulmonary disease (COPD) are among the most common diseases associated with smoking. These conditions frequently present alongside comorbidities including diabetes, coronary heart disease, duodenal ulcer, deep vein thrombosis, pulmonary embolism, osteoporosis and muscle atrophy. Chronic inflammation contributes to the pathology of both periodontitis and COPD, and in patients suffering from both conditions treatment of periodontitis may lead to relief from COPD symptoms as well. Smoking contributes to the underlying pathophysiology by causing local inflammation, increasing the production of proinflammatory cytokines and most importantly, by locally increasing the activity of proteolytic enzymes which degrade the extracellular matrix in both periodontal and lung interstitial tissue. The increase in protease activity and extracellular matrix degradation may explain why periodontitis and COPD comorbidity is so common, a finding which also indicates that therapeutic interventions targeting protease activity and the inflammatory response may be beneficial for both conditions.

Introduction

Periodontal disease is considered to have multiple risk factors. The term “risk factor” refers to the aspect of personal behavior and lifestyle, environmental exposure or an inherited characteristic, which on the basis of epidemiologic evidence is known to be associated with a health-related condition. Risk factors are commonly associated with the pathogenesis of an illness and contribute to the development of the underlying pathophysiological processes either directly or indirectly.

Smoking is a well-established risk factor for periodontitis and bacterial plaque [1]. It is also the most important risk factor for the development of Chronic Obstructive Pulmonary Disease (COPD). It has also been associated with loss of periodontal attachment and bone loss, with individuals with a greater lifetime exposure exhibiting increased risk [2-4]. In cross sectional studies, it is clear that smokers are two to seven times more likely to present periodontitis compared to non-smokers [5-10]. Smoking has also been associated with tooth loss during periodontal maintenance [11,12]. With respect to surgical or non-surgical periodontal therapy, several studies suggest that smoking also compromises the efficacy of treatment and increased the risk for disease recurrence [13].

A recent study [14] evaluated the association between the periodontal status in patients with COPD compared to smokers without COPD, and demonstrated that COPD is an independent risk factor for periodontitis and tooth loss. This study supports also the idea that poor nutritional status (as this confirmed by low serum albumin) in COPD patients might be direct correlated with the reduced chewing ability secondary to periodontitis. Another study conducted in Brazil [9] estimated that smoking cessation programs could result to an approximate reduction of up to 12% of the number of cases of destructive periodontal disease.

Global trends on tobacco consumption suggest that by 2030, it would be one of the leading causes of death with 8 million people per year dying of smoking-related illnesses. It has been reported that smoking reduces the lifespan of an individual by 7 years [15-17]. Smoking has also been associated with cancer, coronary heart disease, Alzheimer’s, cerebrovascular disease and reduced bone mineral density [18,19]. The destructive effects of the aforementioned conditions are mediated through toxic combustion and pyrolysis by-products that trigger the inflammatory response [20]. The production of pro-inflammatory cytokines, such as tumor necrosis factor -a (TNF-a), IL-1, IL-6, IL8, is increased, while that of others such as IL-10, is decreased. Additionally, they activate the function of macrophages and dendritic cells. The level of IgE is elevated leading to immune hypersensitivity reactions. It even weakens the innate defenses against pathogens, alters antigen presentation and promotes autoimmunity [20,21].
It is widely known that both COPD and periodontitis are characterized from neutrophilic inflammation. As mentioned above, patients with periodontitis plus COPD have higher levels of inflammatory cytokines and exhibit increased C-Reactive Protein (CRP) levels, which is a non-specific marker of inflammation [22,23]. Macrophages secrete also IL-4 and IL-13 which cause airway hyperactivity and mucous production [24].

The relationship between dental health and COPD has not been thoroughly elucidated yet. Several studies suggest that periodontal disease was more common in patients with severe COPD than in others severely ill patients with different chronic conditions [25,26]. With this background the current review focuses on the consequences of tobacco smoking on oral health and COPD in adults and the benefits of smoking cessation. It is also intended to clarify the factors underlying increased susceptibility to the harmful effects of smoking and the association between chronic airflow limitation and periodontitis among smokers.

### Tobacco smoking as a risk factor for “inflammaging”

According to the World Health Organization (WHO) “tobacco is one of the greatest emerging disasters in human history.” Recently, it was reported that smoking kills more than 5 million people per year worldwide, which is more than HIV/tuberculosis and malaria together [27]. Cigarette smoking is more prevalent among males (46% in Europe and 56% in Western Pacific). The proportion of female smokers is less than that of males in middle and high income countries (approximately 50% of men versus 20% of women) [26].

Recently, the concept of inflammaging has emerged, which explains the higher basal inflammatory state, characterized by increased circulating cytokines (IL-6, IL-1 and TNF-α) in smokers in the absence of an immune challenge [28-31]. Although a number of studies have considered smoking as a true risk factor for periodontitis and COPD, the mechanisms involved are still not clear. A recent in vitro study [32] showed that nicotine in association with lipopolysaccharide (LPS) from periodontopathogenic bacteria increase the levels of IL-6 as well as IL-8 protein production by human gingival fibroblasts. Another study found that a similar response could be induced by nicotine alone [33]. Higher levels of TNF-α and IL-8 were observed in the gingival crevicular fluid in smokers compared to non-smokers [34]. It seems that cigarette smoking contains potent inhibitors of gene expression and protein production at least for IL-1b, IL8, IL-2 and TNF-α [35]. Studies also suggest that cigarette smoking may underlie increased susceptibility to the harmful effects of smoking and the association between chronic airflow limitation and periodontitis among smokers.

Tobacco smoking and periodontal disease is one of the greatest emerging disasters in human history. It is known that edentulous (total loss of teeth) individuals who had been diagnosed with COPD, were at greater risk of having a COPD related event (hospitalization and death) than those who had teeth and were characterized as having a healthy periodontal status. The risk for COPD related events was attributable to both edentulism and elevated serum IL-6 [41]. These are a number of potential mechanisms that may underlie this association and additional factors that may account for the findings. Due to the fact that COPD is associated with an abnormal inflammatory response of the lung parenchyma to inhaled pollutants and gases, another hypothesis for the detection of systemic inflammation on these patients was that systemic inflammation in COPD was originating in a form of “spillover” of the pulmonary compartment [42].

Cigarette smoke both directly and indirectly initiates inflammation, but other factors sustain inflammation later in the disease process in the absence of cigarette smoke. Analysis of end stage lung tissue obtained from lung volume reduction surgery surprisingly displayed intense inflammation with a variety of cell types present, including macrophages, T-lymphocytes and eosinophils [43,44]. In this study [43] the average time from smoking cessation was nine years. The mechanism by which inflammation is sustained in the absence of cigarette smoking is not known. It may be partly explained by loss of cilia with bacterial colonization and latent viral infection with adenovirus. Also matrix fragments generated by proteinases might lead to a positive feedback loop whereby inflammatory cell proteinases continue to generate extracellular matrix (ECM) fragments, which recruit and activate inflammatory cells with subsequent release of proteinases and further ECM degradation. The reason which edentulism is predictive of COPD-related events is that patients with edentulism have dentures and it is known that biofilm which forms on dentures can house bacteria, yeasts and fungus that result in inflammatory response from oral tissues. Similar to the biofilm on natural teeth, denture biofilm is complex due to the types of organisms it contains, as well as its organized structure. Recently a report [45] was published on the complex nature of the microbial flora contained within the denture biofilm, identifying over 900 individual species of aerobic and anaerobic bacteria, yeasts and amoeboae. Others have reported similar complexities for the microbial content of denture plaque. It has also been long recognized that unlike the dental biofilm, the biofilm that forms on denture materials harbors a much larger population of yeasts, including Candida. Candida albicans in particular has been associated with the presence of denture stomatitis. Since periodontal disease does not lead to major tooth loss in a subset of the population that have a strong inflammatory response to infection, it is likely that infections on dentures will lead to a similar inflammatory response. The increased levels of the inflammatory markers that parallel the severity of periodontal disease in association with higher incidence of COPD-related events support a potential systemic origin of the inflammation and
The mechanisms by which smoking contributes to the pathogenesis of periodontitis are not completely clear. It has been reported that smokers may present a significantly greater plaque index and the average number of bleeding sites in smokers is smaller than in non-smokers [46]. Smokers had a higher prevalence of bacterial species related to periodontal disease compared to non-smokers, including Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Bacteroides forsythus, Prevotella intermedia, Fusobacterium nucleatum [46,47]. Recent studies using real time PCR, have demonstrated a positive relationship between degree of smoking and amount of bacteria/probing depth [48,49].

Several in vitro and in vivo studies [32,33,50,51] have investigated the impact of cigarette smoke constituents, including nicotine and cotinine in the periodontal tissues. Nicotine is just one of the toxic compounds of cigarette smoke. It was demonstrated that the cigarette smoke inhalation enhances periodontal bone destruction in ligature-induced periodontitis [52]. Nicotine adversely affects proliferation, attachment and chemotaxis of periodontal ligament cells and induces pro-inflammatory cytokine production by human gingival fibroblasts synergistically with lipopolysaccharide from E. coli and P. gingivalis. It has also been shown that nicotine increases the production of IL-6 and IL-8 [32]. A microarray analysis demonstrated that peripheral blood mononuclear cells exposed for 5 minutes to tobacco smoke presented an elevated expression of 20 genes previously reported to be associated with periodontal pathogenesis [53].

Higher levels of TNF-a and IL-8 were observed in the gingival crevicular fluid of smokers compared to non-smokers [33]. In contrast, pro and anti-inflammatory cytokines have been reported to be lower in association with smoking and its compounds. It seems that cigarette smoke contains potent inhibitors of both gene expression and protein production.

Pathogenesis of COPD

Several lines of evidence contribute to current concepts of the pathogeneses of COPD. Epidemiological studies suggest that environmental exposure to cigarette smoke is critical [61,62]. Alpha-1 antitrypsin deficiency is also an established cause of COPD, and in this population the disease presents at a much earlier age, regardless of smoking status. Genetic risk factors in addition to Alpha-1 antitrypsin deficiency have been described but the genes are yet to be identified [63,64]. The overall pathogenetic scheme that is emerging for the pathogenesis is that cigarette smoking and less commonly inhalation of other toxic particulates leads to inflammation, with activation and release of elastase and other matrix-degrading proteinases [64,65].

Cigarette smoke leads to recruitment of several inflammatory and immune cell types. These cells release proteinases causing lung tissue destruction. In the normal lung T-lymphocytes in the blood traverse lung tissue and recirculate in regional lymph nodes before returning to the bloodstream. Monocytes enter the lung, differentiate into tissue macrophages and migrate to the alveolar space. In response to cigarette smoke, neutrophils rapidly accumulate in the lung. Recruitment occurs via smoke stimulation of macrophages and structural cells of the lung, such as epithelial cells, resulting in release of neutrophil chemokins, including IL-8, C5a, LTB4 and other mediators. This results in a significant oxidative burden to the lung due to oxidative substances present in smoke and to generated by the recruited inflammatory cells [66]. Oxidative stress also plays a role in cigarette smoke-induced cell death. Fragments of the extracellular matrix proteins such as laminin and fibronectin are also chemotactic for neutrophils and could play a role characterized by matrix proteolysis. Neutrophils also contain preformed proteinases stored in granules. After activation, granules that contain matrix metalloproteinases (particularly MMP1 and MMP-9) are readily released. Granules that contain serine proteinases (neutrophil elastase) are not readily released, although a portion of granules translocate to the cell surface upon activation, where they are difficult to inhibit [63]. COPD is characterized by a gradual and progressive accumulation of macrophages in the lung. Initially, macrophage accumulation is...
most apparent in respiratory bronchioles [64]. COPD is characterized by a gradual and progressive accumulation of macrophages in the lung. Initially, macrophages accumulation is most apparent in respiratory bronchioles [67]. In addition proteolyzed elastin fragments are chemotactic for macrophages [68,69], which produce a variety of MMPs and thus participate directly in lung destruction.

Both CD4 and CD8 cells are also increased in airway walls and alveoli of patients with COPD. Epithelial cells in smokers with COPD have increased expression of CXCL10, the ligand for T-cell CXCXR3 [68]. T-cell products, such as CD40, include MMP expression in several cell types including mononuclear phagocytes [70,71]. Cytotoxic T cells may target epithelial cells and induce cell death, particularly in cells with latent viral infection. Other cells such as dendritic cells, eosinophils and mast cells have also been observed in the lung tissue of patients with COPD, but their role is unclear. Finally, we can postulate that cigarette smoke both directly and indirectly initiates inflammation, but other factors sustain inflammation in the absence of cigarette smoke as mentioned before [43,72].

Matrix metalloproteinases: The missing link?

The matrix metalloproteinases (MMPs) are a family of 24 enzymes that contain a zinc ion at the active site, have overlapping substrate specificity and are inhibited by TIMPS [39,73]. MMPs can degrade basal membrane and extracellular matrix components and therefore they have been classically viewed as effectors of extracellular matrix hydrolysis. However, MMPs have also regulatory properties, modulating enzymes, chemokine and cytokine activities among others, as well as releasing bioactive molecules from extracellular matrix store through limited proteolysis. Because collagen I is the main component of the extracellular soft properties such as collagenases and gelatinases (MMP-5, MMP-2 and MMP-9) play a pivotal role in the loss of periodontal support.

Because collagen I is the main component of the extracellular soft and hard periodontal tissues, MMP5 with collagen-degrading properties such as collagenases and gelatinases (MMP-5, MMP-2 and MMP-9) play a pivotal role in the loss of periodontal support [74-79]. Collagenolytic MMPs have widely been demonstrated in inflamed periodontal tissues and in oral fluids by different analytic methods. MMP-5 can be released and activated during periodontal inflammation by pro-inflammatory cytokines, like TNF-α, IL-1b, reactive oxygen species and proteases derived from subgingival biofilm and the host [80]. Accordingly, higher mRNA expression levels of MMP/TIMP ratios for MMP-1, 2 and 9 as well as RANKL/osteoprotegerin ratio, have been reported in gingival tissue from chronic and aggressive periodontitis compared with healthy gingival tissue [81]. Furthermore, comparison between gingival tissue from aggressive periodontitis and chronic periodontitis showed higher expression of the regulatory cytokines IL-10 and IL-4, and reduced IFN-γ. Besides the importance of a direct collagenolytic role of these MMP in periodontal tissue breakdown, evidence of a relevant MMP regulatory role in periodontitis is emerging. In vitro studies demonstrate the existence of an activation cascade between MMP-14, MMP-13 and MMP-9 [82-84].

Recently, it has been reported that MMP-10 enhance pro-matrix MMP-9 activation rate, which was further prevented by administration of MMP-13 specific synthetic inhibitor in gingival tissue from patients with periodontitis [85]. Higher MMP-14 levels have also been found in gingival tissue from periodontitis subjects compared to controls [86] and reported soluble forms of MMP-14 in periodontitis gingival crevicular fluid [87,88] along with a positive correlation between active MMP-14 and active MMP-13 [89]. These results suggest that collagenolytic MMP-13, MMP-9 and MMP-14 can potentiate their activities through proteolytic activation during periodontal disease, generating amplifying loops [90]. Several MMPs degrade elastin and hence are likely to contribute especially to emphysema, including MMP-2, MMP-9, MMP-7 and MMP-12. MMP-12 has been detected in macrophages of smokers with COPD to a greater degree than in healthy smokers. A search for genetic polymorphisms discovered polymorphisms in the MMP-1 promoter region (the less active promoter had worse lung function) and in MMP-12, which together correlated with the rate of lung function decline [40].

Several animal models have supported roles for MMP-5 in COPD. Transgenic mice constitutively overexpressing MMP-1 were found to develop air space enlargement [91]. Mice lacking MMP-12 were resistant to long term cigarette smoke-induced emphysema. Subsequent studies have shown that mice deficient in avB6 develop spontaneous emphysema over time [92]. In the absence of avB6, there is no transforming growth factor-B (TGF-b). Because TGF-b normally inhibits MMP-12, avB6 mice have 100-fold excess MMP12 and consequently develop emphysema, while mice that inducibly overexpress IL-13 develop inflammation and expression of MMP-9, MMP-12 and cathepsin-S with consequent emphysema.

Smoking cessation in periodontitis and COPD

It is not clear how long after smoking discontinuance the patient recovers its normal inflammatory conditions. One study [93] suggested that there is an increase of CD8 T-cells and a decrease of the CD4/CD8 ratio within 6 months after smoking cessation. Another [35] stated that it takes more than 8 weeks for levels of IL-1b, IL-8 and TNF-α to return to their normal values and that normal levels of neutrophil function have not been completely recovered after this period. On the other hand analysis of end stage lung tissue obtained from lung volume reduction surgery surprisingly displayed intense inflammation composed of a variety of cell types, including macrophages, T-cells, neutrophils and eosinophils [43]. The mechanism by which inflammation is sustained in the absence of cigarette smoke is still not known. Matrix fragments generated by proteases might lead to a positive feedback loop whereby inflammatory cell proteases continue to generate extracellular matrix fragments, which recruit and activate inflammatory cells with subsequent release of proteases and further extracellular matrix degradation.

It is clear that multiple inflammatory cell types are present and interact to cause periodontitis and COPD. Rather than focusing in individual cell types, it is the interaction among these cells that is the appropriate target of studies of disease pathogenesis. In addition, structural cells not only are an additional source of proteinases, their viability and ability to repair are critical to the structural integrity of the periodontium and lung [94,95].

Conclusions

Based on the empirical data from studies published in recent years, it seems that smoking is a potent risk factor for the development of both COPD and periodontitis, two conditions which are frequently comorbid. It seems that there is an increased concentration of some inflammatory mediators and a decreased concentration of others concerning the pathogenetic mechanisms of those
two diseases. The activation of proteolytic enzymes (induced by the interaction between cigarette smoke components and the immune system) which degrade extracellular matrix components is central to the pathogenesis of both conditions and the underlying pathophysiological processes may be linked. Further studies are required to shed light on the association between COPD and periodontitis, and to establish whether modulation of the immune response (for example by administration of immunosuppressant drugs or interleukin antagonists) may be clinically utilized for the treatment of these conditions.

References